Nice cup and handle formation, anticipated stronger than forecasted earning to come Jul 28th. Presume we will catch some cross winds from Moderna's momentum. Setting a target price of $50 / share and would love to hear your thoughts!
Wednesday morning, Pfizer unveiled its Q2 figures. They revealed that the pharmaceutical sector giant earned revenue of $19 billion, a robust 86% higher than in the same quarter of 2020. Much of this was, of course, due to the BNT162b2 coronavirus vaccine it's developed with Germany-based BioNTech. But even stripping out the vaccine's sales from the top line, the company still managed to grow revenue by 10% to $11.1 billion. On average, analysts tracking Pfizer stock were modeling $18.45 billion.
Quoted by the company as saying the quarter was "remarkable," CEO Albert Bourla signaled optimism for the coming years. He and his troops believe Pfizer will be able to hit a 6% compound annual revenue growth rate through 2025.
With that powerful quarter behind it, the confident Pfizer has upped its full-year guidance. It now expects $78 billion to $80 billion in revenue (previous estimate: $70.5 billion to $72.5 billion), and adjusted diluted per-share earnings of $3.95 to $4. 05 (up from $3.55 to $3.65).
stsoumpas
⋅
@MaDasurfer, Very well said. You have a target price in mind?
TheRealRCD
⋅
With the whole world buying Pfizer covid vaccine by the truckload I can't see this go anywhere but ballistic.
drharrison1
⋅
Do you want think we see a 50$ Pfizer ? If so by when ?
stsoumpas
⋅
@drharrison1, I think $65 is attainable at this point given the wind of the markets and how large of sails PFE has, but obviously beware the winds can shift rather quickly with how fragile the market really is.
Very steady incremental growth on top of anticipated news stacked on more anticipated news with the boosters to be coming out on top of FDA approval for vaccine for children and, and, and....
My target price to exit $45 calls I took first week of July is $50 by end of Aug with sept exp
MaDasurfer
⋅
@drharrison1, Wednesday morning, Pfizer unveiled its Q2 figures. They revealed that the pharmaceutical sector giant earned revenue of $19 billion, a robust 86% higher than in the same quarter of 2020. Much of this was, of course, due to the BNT162b2 coronavirus vaccine it's developed with Germany-based BioNTech. But even stripping out the vaccine's sales from the top line, the company still managed to grow revenue by 10% to $11.1 billion. On average, analysts tracking Pfizer stock were modeling $18.45 billion.
Quoted by the company as saying the quarter was "remarkable," CEO Albert Bourla signaled optimism for the coming years. He and his troops believe Pfizer will be able to hit a 6% compound annual revenue growth rate through 2025.
With that powerful quarter behind it, the confident Pfizer has upped its full-year guidance. It now expects $78 billion to $80 billion in revenue (previous estimate: $70.5 billion to $72.5 billion), and adjusted diluted per-share earnings of $3.95 to $4. 05 (up from $3.55 to $3.65).
Target $44 and $46